Alpine Immune Sciences, Inc. (NASDAQ:ALPN) Receives Average Recommendation of “Hold” from Analysts

Alpine Immune Sciences, Inc. (NASDAQ:ALPN) has been assigned an average rating of “Hold” from the eleven research firms that are covering the firm, Marketbeat.com reports. Eight equities research analysts have rated the stock with a hold rating and three have issued a buy rating on the company. The average twelve-month price objective among brokers that have updated their coverage on the stock in the last year is $50.33.

A number of analysts have recently weighed in on ALPN shares. Leerink Partnrs cut shares of Alpine Immune Sciences from an “outperform” rating to a “market perform” rating in a report on Thursday, April 11th. Wolfe Research reiterated a “peer perform” rating on shares of Alpine Immune Sciences in a research note on Thursday, April 11th. Morgan Stanley reiterated an “equal weight” rating and issued a $65.00 target price (up from $47.00) on shares of Alpine Immune Sciences in a research note on Thursday, April 11th. Guggenheim assumed coverage on shares of Alpine Immune Sciences in a research note on Tuesday, April 9th. They issued a “buy” rating and a $55.00 target price for the company. Finally, TD Cowen reiterated a “hold” rating on shares of Alpine Immune Sciences in a research note on Tuesday, April 16th.

Institutional Trading of Alpine Immune Sciences

Several institutional investors and hedge funds have recently bought and sold shares of the business. Allspring Global Investments Holdings LLC grew its holdings in shares of Alpine Immune Sciences by 745.5% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 1,488 shares of the biotechnology company’s stock worth $28,000 after buying an additional 1,312 shares in the last quarter. AJOVista LLC purchased a new stake in shares of Alpine Immune Sciences during the fourth quarter worth $64,000. Barclays PLC grew its holdings in shares of Alpine Immune Sciences by 44.3% during the third quarter. Barclays PLC now owns 9,126 shares of the biotechnology company’s stock worth $104,000 after buying an additional 2,801 shares in the last quarter. Tower Research Capital LLC TRC grew its holdings in shares of Alpine Immune Sciences by 411.6% during the fourth quarter. Tower Research Capital LLC TRC now owns 5,490 shares of the biotechnology company’s stock worth $105,000 after buying an additional 4,417 shares in the last quarter. Finally, New York State Common Retirement Fund grew its holdings in shares of Alpine Immune Sciences by 75.8% during the third quarter. New York State Common Retirement Fund now owns 9,634 shares of the biotechnology company’s stock worth $110,000 after buying an additional 4,155 shares in the last quarter. 75.17% of the stock is currently owned by institutional investors and hedge funds.

Alpine Immune Sciences Stock Performance

NASDAQ:ALPN opened at $64.62 on Friday. Alpine Immune Sciences has a fifty-two week low of $6.71 and a fifty-two week high of $64.70. The stock has a market capitalization of $4.24 billion, a P/E ratio of -100.97 and a beta of 1.14. The company’s 50-day simple moving average is $42.90 and its 200-day simple moving average is $26.26.

Alpine Immune Sciences (NASDAQ:ALPN) last released its quarterly earnings results on Monday, March 18th. The biotechnology company reported $0.15 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.32) by $0.47. Alpine Immune Sciences had a negative net margin of 54.66% and a negative return on equity of 15.54%. The business had revenue of $30.85 million for the quarter, compared to analysts’ expectations of $6.90 million. On average, research analysts forecast that Alpine Immune Sciences will post -1.74 EPS for the current year.

About Alpine Immune Sciences

Alpine Immune Sciences, Inc operates as a clinical-stage biopharmaceutical company. It focuses on the discovery and development of immunotherapies through protein engineering technologies for treating autoimmune and inflammatory diseases. The company's product pipeline includes Povetacicept, a dual B cell cytokine antagonist, which is in Phase 2 clinical trial for the treatment of multiple autoimmune and inflammatory diseases; and Acazicolcept, a dual inhibitor of the CD28 and ICOS T cell costimulatory pathways that is in preclinical trial for the treatment of systemic lupus erythematosus.